Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data
2020
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
Membrane curvature regulates the spatial distribution of bulky glycoproteins
2022 StandoutNobel
Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
2010
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development
2015
Quantitative structure–pharmacokinetic/pharmacodynamic relationships
2006
Hypoxia, inflammation, and the tumor microenvironment in metastatic disease
2010
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Cancer to bone: a fatal attraction
2011 Standout
Contribution of platelets to tumour metastasis
2011 Standout
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
The cancer glycocalyx mechanically primes integrin-mediated growth and survival
2014 StandoutNatureNobel
Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy
2011
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates
2015
PLGA-based nanoparticles: An overview of biomedical applications
2012 Standout
O-Pair Search with MetaMorpheus for O-glycopeptide characterization
2020 StandoutNobel
Crohn's disease
2012 Standout
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Applying Linear and Non-Linear Methods for Parallel Prediction of Volume of Distribution and Fraction of Unbound Drug
2013
Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias
2007
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
2018
Quantitative structure–pharmacokinetic relationships for drug clearance by using statistical learning methods
2005
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
2007 Standout
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
2010 Standout
Extracellular matrix structure
2015 Standout
Integrins as “functional hubs” in the regulation of pathological angiogenesis
2009
Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions
2012
Revealing the human mucinome
2022 StandoutNobel
Pharmacological characterization of PF‐00547659, an anti‐human MAdCAM monoclonal antibody
2009
Remodelling the extracellular matrix in development and disease
2014 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Glycosylation in health and disease
2019
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis
2009
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Catheter-directed Thrombolysis in Deep Venous Thrombosis with Use of Reteplase: Immediate Results and Complications from a Pilot Study
2002
Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy
2009
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Pancreatic Cancer
2010 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Prospects for MEK inhibitors for treating cancer
2014
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
2010 Standout
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
2017 Standout
De novo design of tyrosine and serine kinase-driven protein switches
2021 StandoutNobel
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
The transport of organic cations in the small intestine: Current knowledge and emerging concepts
2006
Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
2008
Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
β1-Integrin: A Potential Therapeutic Target in the Battle against Cancer Recurrence
2011
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial
2005 Standout
The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention.
2005
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
2015 Standout
Cost and outcome implications of the organisation of vascular services.
2000
Diabetes and Cancer
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Electron-Based Dissociation Is Needed for O-Glycopeptides Derived from OpeRATOR Proteolysis
2020 StandoutNobel
The extracellular matrix at a glance
2010 Standout
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
2011
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
The inclusion of reports of randomised trials published in languages other than English in systematic reviews
2003
Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
2012
CBTF: New Amine-to-Thiol Coupling Reagent for Preparation of Antibody Conjugates with Increased Plasma Stability
2015
Selenium Nanoparticles as a Carrier of 5-Fluorouracil to Achieve Anticancer Synergism
2012
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
A bulky glycocalyx fosters metastasis formation by promoting G1 cell cycle progression
2017 StandoutNobel
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Works of Chee M. Ng being referenced
Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys
2014
Pharmacokinetics/Pharmacodynamics of Nondepleting Anti-CD4 Monoclonal Antibody (TRX1) in Healthy Human Volunteers
2005
Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis
2006
Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis
2005
Quantitative structure–activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance-associated protein 2 (rMrp2)
2005
Secretory Transport of Ranitidine and Famotidine across Caco-2 Cell Monolayers
2002
Quantitative structure−pharmacokinetic parameters relationships (QSPKR) analysis of antimicrobial agents in humans using simulated annealing k‐nearest‐neighbor and partial least‐square analysis methods**This paper was presented in part at the Annual Meeting of the American Association of Pharmaceutical Scientists in Toronto in 2003.
2004
PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts
2012
Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial
2005
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples
2007
Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function
2007
Pharmacokinetics (PK) of pertuzumab (rhuMAb 2C4) in phase II studies of ovarian, breast, prostate, and lung cancers
2005
Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T‐Cell Therapy
2019
The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab
2006
A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer
2007
Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation
2004
Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
2008
Meta-analysis of streptokinase and heparin in deep vein thrombosis
1998